1
|
Chan T, Koch SN, Devine S, Mendoza-Kuznetsova E. Oclacitinib therapy in two cats with refractory proliferative and necrotising otitis externa. Vet Dermatol 2024. [PMID: 38818665 DOI: 10.1111/vde.13269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2024] [Revised: 03/26/2024] [Accepted: 05/20/2024] [Indexed: 06/01/2024]
Abstract
Feline proliferative and necrotising otitis externa (PNOE) is a rare immune-mediated condition, usually self-limiting or responsive to immunosuppressants such as topical tacrolimus. This case report describes two cats with refractory PNOE that responded successfully to oclacitinib. One cat also had middle ear involvement and the other cat had extra-auricular dermatitis.
Collapse
Affiliation(s)
- Tim Chan
- Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA
| | - Sandra Nogueira Koch
- Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, Saint Paul, Minnesota, USA
| | - Samuel Devine
- Cummings School of Veterinary Medicine at Tufts University, North Grafton, Massachusetts, USA
| | | |
Collapse
|
2
|
Pérez-Aranda M, Yotti C, Pérez J, Ginel PJ. Successful treatment of sebaceous adenitis with oclacitinib and low-dose prednisolone in a dog. Vet Dermatol 2024; 35:238-241. [PMID: 37968244 DOI: 10.1111/vde.13216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Revised: 08/24/2023] [Accepted: 10/30/2023] [Indexed: 11/17/2023]
Abstract
Finding an effective and well-tolerated treatment for canine idiopathic sebaceous adenitis (ISA) can be challenging. This case report describes an 8-year-old male Rottweiler with ISA successfully treated with a combination of oclacitinib and low doses of prednisolone.
Collapse
Affiliation(s)
| | - César Yotti
- SKINPET Medivet Veterinary Dermatology Center, Madrid, Spain
| | - Judith Pérez
- SKINPET Medivet Veterinary Dermatology Center, Madrid, Spain
| | - Pedro J Ginel
- Department of Animal Medicine and Surgery, University of Córdoba, Córdoba, Spain
| |
Collapse
|
3
|
Congiusta MC, Snyder C, Soukup JW, Apostolopoulos N. Novel Management of Masticatory Myositis in Three Dogs with a Selective Janus Kinase (JAK-1) Inhibitor. J Vet Dent 2024:8987564231219925. [PMID: 38192103 DOI: 10.1177/08987564231219925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2024]
Abstract
Masticatory myositis (MM) is an inflammatory myopathy reported in dogs and is characterized by inflammation of the masticatory muscles (temporalis, masseter, and pterygoid muscles). Immunosuppressive therapy is the current recommended treatment for MM and may involve glucocorticoids, cyclosporine, azathioprine, mycophenolate mofetil, leflunomide, or a combination of these treatments that are slowly tapered to the lowest effective dose. However, side effects from multimodal medical therapy and complications associated with MM relapses have been reported. The purpose of this case series was to report oclacitinib as a treatment alternative to traditional medical management of MM. The intent of this alternative is to manage side effects from glucocorticoid use. Oclacitinib (1mg/kg per os q12h) was used solely for treatment of MM in three dogs. The dogs were followed up to >6 months after oclacitinib administration. An increase in oral range of motion, as determined by gape angle, was noted in all three dogs. However, a corresponding drop in antibody titers (2M fiber) did not occur. All dogs showed improvement in overall clinical management of MM, side effects from glucocorticoids, and clinical signs related to chronic prednisone use. Larger controlled trials with consistent measurements (interincisal distance, gape angle) and 2M fiber antibody titers are indicated to further assess validation of oclacitinib treatment of MM. The clinical outcome of all dogs was considered successful.
Collapse
Affiliation(s)
- Michael C Congiusta
- Dentistry and Oral Surgery, Department of Surgical Sciences, School of Veterinary Medicine; University of Wisconsin-Madison, Madison, WI, USA
| | - Christopher Snyder
- Dentistry and Oral Surgery, Department of Surgical Sciences, School of Veterinary Medicine; University of Wisconsin-Madison, Madison, WI, USA
| | - Jason W Soukup
- Dentistry and Oral Surgery, Department of Surgical Sciences, School of Veterinary Medicine; University of Wisconsin-Madison, Madison, WI, USA
| | - Neoklis Apostolopoulos
- Dermatology, Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA
| |
Collapse
|
4
|
Hernandez-Bures A, Bidot WA, Griffin CE, Rosenkrantz WS. The use of oclacitinib compared to azathioprine in the management of canine pemphigus foliaceus: A retrospective analysis. Vet Dermatol 2023; 34:554-566. [PMID: 37700599 DOI: 10.1111/vde.13203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2023] [Revised: 06/07/2023] [Accepted: 08/26/2023] [Indexed: 09/14/2023]
Abstract
BACKGROUND Oclacitinib (Apoquel; Zoetis) has been reported to be beneficial for treating immune-mediated disorders. HYPOTHESIS/OBJECTIVES This retrospective study evaluates in which group of dogs [oclacitinib (OC) or azathioprine (AZ)] remission of pemphigus foliaceus (PF) was more effectively achieved with matched induction dosing of glucocorticoids; it further evaluates which group had a higher glucocorticoid-sparing effect. ANIMALS Review of 30 medical records of dogs diagnosed with PF presented to a private practice dermatological service. MATERIALS AND METHODS Retrospective analysis of dogs diagnosed with PF and treated with OC or AZ in combination with glucocorticoids. RESULTS There was no significant difference in the ability to induce remission between AZ and OC groups. In the AZ group, 13 of 15 dogs went into some type of remission (partial or complete), compared with 11 of 15 in the OC group. There was no significant difference between the two groups for the glucocorticoid-sparing effect. The AZ group had an average reduction of 77.9% from the induction glucocorticoid dose, and OC group had an average reduction of 64.4%. One of 15 patients in the AZ group and three of 15 patients in the OC group had a 100% reduction of the glucocorticoid dose. CONCLUSIONS AND CLINICAL RELEVANCE These results indicate that OC can be considered as a treatment option for canine PF.
Collapse
Affiliation(s)
| | - Wille A Bidot
- Office of Animal Resources, Western University of Health Sciences, Pomona, California, USA
| | | | | |
Collapse
|
5
|
Harvey R, Horton H. Successful treatment of perianal fistulas in two dogs with oclacitinib. Vet Dermatol 2023; 34:483-486. [PMID: 37184056 DOI: 10.1111/vde.13171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2022] [Revised: 03/14/2023] [Accepted: 03/27/2023] [Indexed: 05/16/2023]
Abstract
Perianal fistula (PAF) formation in dogs is a frustrating and painful disease, occurring primarily in German shepherd dogs. Ciclosporin has become the recommended treatment of choice yet may be associated with numerous adverse effects. This case report describes the successful treatment of two cases of PAF with oclacitinib.
Collapse
|
6
|
Banovic F, Olivry T, Artlet B, Rothstein E, Beco L, Linek M, Zabel S, Peters-Kennedy J, Welle M, Wilkes R, Austel M, Linder K. Hyperkeratotic erythema multiforme variant in 17 dogs. Vet Dermatol 2023; 34:125-133. [PMID: 36510641 DOI: 10.1111/vde.13141] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Revised: 10/05/2022] [Accepted: 10/15/2022] [Indexed: 12/15/2022]
Abstract
BACKGROUND A new canine subgroup defined as 'old-dog' or 'hyperkeratotic' erythema multiforme (HKEM) with marked hyperkeratosis and parakeratosis has been proposed without any detailed description of larger case series. OBJECTIVES We report herein the signalment, clinical signs, treatment outcome, and histopathological and immunological findings in 17 dogs with HKEM. ANIMALS Inclusion criteria were the presence of (i) scaly skin lesions with or without crusting; and (ii) microscopic lesions typical of EM (i.e. a panepidermal cytotoxic lymphocytic dermatitis with or without basal keratinocyte apoptosis); and (iii) microscopic ortho- and/or parakeratotic hyperkeratosis affecting the interfollicular epidermis. MATERIALS AND METHODS Clinical questionnaires and skin biopsies were reviewed. Polymerase chain reactions for epidermotropic viruses and direct immunofluorescence were performed. RESULTS Various breeds were affected with an over-representation of males in their mid-to-late adulthood (median age 9 years). Generalised skin lesions included multifocal-to-coalescing, linear and annular macules and plaques with erythema and adherent firm crusting. Microscopic lesions were specific for EM and featured prominent superficial epidermal apoptosis with lymphocytic satellitosis and parakeratosis. No drug triggers were identified. Polymerase chain reactions for canine herpesvirus polymerase gene, canine parvovirus and canine distemper virus were negative in all HKEM and canine erosive EM (15 dogs) biopsies. Lesions failed to respond to oral and/or topical antimicrobials. Complete remission of signs was achieved in 9 of 17 dogs (53%) using immunosuppressive regimens. CONCLUSIONS AND CLINICAL RELEVANCE Hyperkeratotic erythema multiforme (HKEM) is a chronic, persistent and clinically distinctive erythema multiforme (EM) variant that differs from 'classic' vesiculobullous erosive-to-ulcerative EM in dogs.
Collapse
Affiliation(s)
- Frane Banovic
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA
| | - Thierry Olivry
- Department of Clinical Sciences, College of Veterinary Medicine, NC State University, Raleigh, North Carolina, USA
| | - Barbara Artlet
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA
| | - Emily Rothstein
- Animal Allergy and Dermatology Service of Connecticut, Plantsville, Connecticut, USA
| | - Luc Beco
- Cabinet Vétérinaire, Spa, Belgium
| | | | - Sonja Zabel
- VCA Northwest Veterinary Specialist, Dermatology, Allergy & Otology Service, Clackamas, Oregon, USA
| | - Jeanine Peters-Kennedy
- Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA
| | - Monika Welle
- Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
| | - Rebecca Wilkes
- Department of Comparative Pathobiology/Animal Disease Diagnostic Laboratory, Purdue University College of Veterinary Medicine, West Lafayette, Indiana, USA
| | - Michaela Austel
- Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA
| | - Keith Linder
- Department of Population Health and Pathobiology, College of Veterinary Medicine, NC State University, Raleigh, North Carolina, USA
| |
Collapse
|
7
|
De Bellis F, Di Mattia D. Approach to emergency dermatology cases in dogs and cats. IN PRACTICE 2022. [DOI: 10.1002/inpr.247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
8
|
Carrasco I, Ferrer L, Puigdemont A. Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response. J Feline Med Surg 2022; 24:787-793. [PMID: 34612749 PMCID: PMC10812271 DOI: 10.1177/1098612x211048458] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
OBJECTIVES The aim of this study was to assess the efficacy of a new therapeutic regimen of oclacitinib for the control of feline atopic skin syndrome (FASS) and to correlate plasma levels of this drug with clinical effects. METHODS Twenty-eight client-owned cats with a clinical diagnosis of FASS were recruited. Oclacitinib was administered at 1 mg/kg q12h for 2 weeks and then at 1 mg/kg q24h for a further 2 weeks. At the study outset (D0), and 7 (D7) and 28 (D28) days after starting treatment, clinical lesions were assessed using a validated scoring system (SCORing Feline Allergic Dermatitis [SCORFAD]) and pruritus was graded via an adapted visual analogue scale (PVAS). At the same time points, plasma oclacitinib levels and haematological variables were measured. RESULTS Among 18 cats completing the study, PVAS and SCORFAD improved by ⩾50% in 61% and 88% of animals, respectively. Mean PVAS decreased significantly between D0 and D7 and between D0 and D28 (both P <0.001) but not between D7 and D28. Likewise, mean SCORFAD values decreased significantly between D0 and D7 and between D0 and D28 (both P <0.001) but not between D7 and D28. On D7 and D28, plasma oclacitinib concentrations varied widely from 0 to 1443.2 ng/ml and from from 0 to 1177.7 ng/ml, respectively. Oclacitinib concentrations showed no correlation with clinical effects (SCORFAD and PVAS). CONCLUSIONS AND RELEVANCE Oclacitinib emerged as being safe and effective to control clinical signs of FASS. A mean dose of 1 mg/kg, even without extending twice-daily treatment beyond the first 2 weeks, could be a suitable therapeutic regimen. Plasma drug levels did not seem useful to predict clinical response during treatment.
Collapse
Affiliation(s)
- Isaac Carrasco
- Department of Pharmacology, Therapeutics and Toxicology, Universitat Autonoma de Barcelona, Campus de Bellaterra, Bellaterra, Barcelona, Spain
| | - Lluis Ferrer
- Department of Animal Medicine and Surgery, Universitat Autonoma de Barcelona, Campus de Bellaterra, Bellaterra, Barcelona, Spain
| | - Anna Puigdemont
- Department of Pharmacology, Therapeutics and Toxicology, Universitat Autonoma de Barcelona, Campus de Bellaterra, Bellaterra, Barcelona, Spain
| |
Collapse
|
9
|
Denti D, Caldin M, Ventura L, De Lucia M. Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs. Vet Dermatol 2022; 33:149-e42. [PMID: 35014745 DOI: 10.1111/vde.13053] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 09/15/2021] [Accepted: 11/09/2021] [Indexed: 12/21/2022]
Abstract
BACKGROUND Oclacitinib administered at the licensed dose twice daily for two weeks and then once daily as required is recommended for the treatment of atopic dogs. In some cases, the once-daily regimen is insufficient to control the clinical signs. OBJECTIVES To provide preliminary safety and efficacy data on the prolonged twice-daily administration of oclacitinib in atopic dogs. ANIMALS Fifty-three client-owned atopic dogs. METHODS AND MATERIALS The medical records of dogs with atopic dermatitis treated with oclacitinib twice daily for more than two weeks were reviewed retrospectively. Animal details, treatment dose and duration, concurrent diseases, adjunctive medications and possible adverse events were recorded. Treatment efficacy was assessed retrospectively and, when available, the selected blood parameters before and during the treatment were compared. Statistical analyses of the collected data were performed. RESULTS The median treatment duration was 113 days. Excellent-to-good efficacy was observed in 38 dogs (72%), including 24 of 33 dogs that failed to respond to the once-daily regimen. Eight dogs showed a poor response despite the addition of systemic glucocorticoids. Pyoderma, gastrointestinal signs and otitis externa were the most frequent adverse events recorded whilst on treatment. Blood tests performed in 35 dogs showed slightly decreased leucocyte, neutrophil, eosinophil and monocyte counts that remained within the reference ranges in most cases. Three dogs developed hypercholesterolemia. CONCLUSIONS AND CLINICAL RELEVANCE Prolonged twice-daily administration of oclacitinib generally was well-tolerated and was effective in most of the treated dogs. Regular clinical evaluation and blood tests are advisable for this treatment regimen.
Collapse
Affiliation(s)
- Daria Denti
- Dermatology Unit, San Marco Veterinary Clinic and Laboratory, Via dell'Industria 3, Veggiano, 35030, Italy
| | - Marco Caldin
- Pathology Unit, San Marco Veterinary Clinic and Laboratory, Via dell'Industria 3, Veggiano, 35030, Italy
| | - Laura Ventura
- Department of Statistical Sciences, University of Padova, Via Cesare Battisti 241, Padova, 35121, Italy
| | - Michela De Lucia
- Dermatology Unit, San Marco Veterinary Clinic and Laboratory, Via dell'Industria 3, Veggiano, 35030, Italy
| |
Collapse
|
10
|
Quilling LL, Lam ATH, Outerbridge CA, White SD. Treatment of crusted sarcoptic mange with fluralaner in a dog. VETERINARY RECORD CASE REPORTS 2021. [DOI: 10.1002/vrc2.109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- Laura L. Quilling
- University of California William R. Pritchard Veterinary Medical Teaching Hospital 1 Garrod Drive Davis CA 95616
| | - Andrea T. H. Lam
- University of California William R. Pritchard Veterinary Medical Teaching Hospital 1 Garrod Drive Davis CA 95616
| | - Catherine A. Outerbridge
- University of California William R. Pritchard Veterinary Medical Teaching Hospital 1 Garrod Drive Davis CA 95616
| | - Stephen D. White
- University of California William R. Pritchard Veterinary Medical Teaching Hospital 1 Garrod Drive Davis CA 95616
| |
Collapse
|
11
|
Colombo S, Cornegliani L, Vercelli A, Fondati A. Ear tip ulcerative dermatitis treated with oclacitinib in 25 dogs: a retrospective case series. Vet Dermatol 2021; 32:363-e100. [PMID: 34250688 DOI: 10.1111/vde.12992] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Revised: 04/19/2021] [Accepted: 04/22/2021] [Indexed: 12/23/2022]
Abstract
BACKGROUND Ear tip ulcerative dermatitis (ETUD) is an uncommon clinical reaction pattern in canine dermatology. The lesions are suggestive of vascular damage which may be caused by inflammatory or noninflammatory diseases, and often are idiopathic. Therapeutic options for ETUD include topical glucocorticoids or tacrolimus, pentoxifylline, vitamin E, doxycycline, tetracycline and niacinamide, sulfonamides, glucocorticoids, ciclosporin and surgical correction. HYPOTHESIS/OBJECTIVES The aims of this retrospective case series were to describe the clinical features and report response to treatment with oclacitinib in dogs with idiopathic, chronic ETUD. ANIMALS Twenty-five privately owned dogs with unilateral or bilateral ETUD. METHODS AND MATERIALS Cases of ETUD which were poorly responsive to conventional therapy and subsequently treated with oclacitinib, are summarised. All cases were tested for leishmaniosis by serological examination [indirect fluorescent antibody test (IFAT) or enzyme-linked immunosorbent assay (ELISA)]. Histopathological examination was performed in two cases. RESULTS Serological results were negative for leishmaniosis in all dogs. Histopathological changes consistent with proliferative thrombovascular necrosis of the pinnae were documented in two cases. Oclacitinib, used at the standard dose range recommended for the treatment of canine atopic dermatitis, effectively resolved ETUD in 22 of 25 dogs within one to three months. Several of the dogs required prolonged use of twice daily dosing. CONCLUSIONS AND CLINICAL RELEVANCE Oclacitinib should be included among the therapeutic options for ETUD, once infectious diseases have been ruled out.
Collapse
Affiliation(s)
- Silvia Colombo
- Servizi Dermatologici Veterinari, via Felice Musazzi 24, Legnano, MI, I-20025, Italy
| | - Luisa Cornegliani
- Clinica Veterinaria Città di Torino, c.so Traiano 99/d, Torino, I-10135, Italy
| | - Antonella Vercelli
- Clinica Veterinaria Città di Torino, c.so Traiano 99/d, Torino, I-10135, Italy
| | - Alessandra Fondati
- Clinica Veterinaria Colombo, Viale Cristoforo Colombo 153, Lido di Camaiore, LU, I-55041, Italy
| |
Collapse
|
12
|
Panzuti P, Jongh O, Dony M, Vial S, Mosca M, Pin D. Extra-auricular lesions of proliferative and necrotizing otitis externa in three kittens. Vet Dermatol 2021; 32:385-e110. [PMID: 33961315 DOI: 10.1111/vde.12968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/24/2021] [Indexed: 11/28/2022]
Abstract
BACKGROUND Proliferative and necrotising otitis externa (PNOE) is a rare disorder in cats with poorly understood pathogenesis. Extra-auricular (EA) lesions recently have been mentioned in a textbook and in one case report. OBJECTIVES To describe EA lesions associated with PNOE in three kittens. ANIMALS A 6-month-old female domestic short hair (DSH) cat (Case 1), an 8-month-old female DSH cat (Case 2) and a 5-month-old female DSH cat (Case 3). METHODS AND RESULTS All cases exhibited classical lesions of PNOE associated with EA lesions, generalised (cases 1 and 3) or limited to eyelids (Case 2). Lesions were characterised by thick, adherent, hyperkeratotic papules coalescing to plaques and attempts to remove the hyperkeratotic plaques resulted in erosions. Histopathological examinations revealed classical features of PNOE: severe acanthosis associated with a marked lymphocytic exocytosis, satellitosis and apoptotic keratinocytes at all levels of the epidermis and the outer root sheath of hair follicles. Cases 2 and 3 resolved spontaneously. Case 1 remained stable with topical tacrolimus and oral prednisolone after a short course of ciclosporin. CONCLUSIONS AND CLINICAL IMPORTANCE This report describes EA lesions of PNOE in three kittens. Such lesions may be underdiagnosed, and this report emphasises the role of a thorough clinical inspection in PNOE cases.
Collapse
Affiliation(s)
- Pauline Panzuti
- Université de Lyon, VetAgro Sup, UP ICE, Marcy l'Etoile, F-69280, France
| | - Olivier Jongh
- Université de Lyon, VetAgro Sup, UP ICE, Marcy l'Etoile, F-69280, France.,Clinique vétérinaire des Drs Anjolras, Jongh et Aragon, Neuville-sur-Saône, F-69250, France
| | - Manoëlle Dony
- Clinique vétérinaire d'Auneuil, Auneuil, F-60390, France
| | - Stéphanie Vial
- Université de Lyon, VetAgro Sup, UP ICE, Marcy l'Etoile, F-69280, France
| | - Marion Mosca
- Université de Lyon, VetAgro Sup, UP ICE, Marcy l'Etoile, F-69280, France
| | - Didier Pin
- Université de Lyon, VetAgro Sup, UP ICE, Marcy l'Etoile, F-69280, France
| |
Collapse
|
13
|
Carrasco I, Martínez M, Albinyana G. Beneficial effect of oclacitinib in a case of feline pemphigus foliaceus. Vet Dermatol 2021; 32:299-301. [PMID: 33720467 DOI: 10.1111/vde.12949] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/07/2020] [Indexed: 01/12/2023]
Abstract
Pemphigus foliaceous (PF) is a pustular, immune-mediated skin disease characterised by acantholytic cells and commonly treated with high doses of glucocorticoids. This report describes one case of feline PF successfully controlled using oral oclacitinib, suggesting a possible therapeutic alternative to glucocorticoids in some cases.
Collapse
Affiliation(s)
- Isaac Carrasco
- Servicio Dermatología Hospital Veterinario Canis, Agnés de Pacs 12, Palma de Mallorca, 07010, Spain
| | - Marta Martínez
- Servicio Dermatología Hospital Veterinario Canis, Agnés de Pacs 12, Palma de Mallorca, 07010, Spain
| | | |
Collapse
|
14
|
Shared inflammatory and skin-specific gene signatures reveal common drivers of discoid lupus erythematosus in canines, humans and mice. CURRENT RESEARCH IN IMMUNOLOGY 2021; 2:41-51. [PMID: 35492392 PMCID: PMC9040131 DOI: 10.1016/j.crimmu.2021.03.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2020] [Revised: 03/19/2021] [Accepted: 03/21/2021] [Indexed: 12/29/2022] Open
Abstract
Autoimmune skin diseases are complex and are thought to arise from a combination of genetics and environmental exposures, which trigger an ongoing immune response against self-antigens. Companion animals including cats and dogs are known to develop inflammatory skin conditions similar to humans and share the same environment, providing opportunities to study spontaneous disease that encompasses genetic and environmental factors with a One Health approach. A strength of comparative immunology approaches is that immune profiles may be assessed across different species to better identify shared or conserved pathways that might drive inflammation. Here, we performed a comparative study of skin from canine discoid lupus erythematosus (DLE) using NanoString nCounter technology. We compared these gene expression patterns to those of human DLE and a mouse model of cutaneous lupus. We found strong interferon signatures, with CXCL10, ISG15, and an S100 gene family member among the highest, most significant DEGs upregulated across species. Cell type analysis revealed marked T-cell and B-cell infiltration. Interestingly, canine DLE samples also recapitulated downregulated skin homeostatic genes observed in human DLE. We conclude that spontaneous DLE in dogs captures many features that are present in human disease and may serve as a more complete model for conducting further genomic and/or transcriptomic studies. Canine DLE lesions express known drivers of pathogenesis including CXCL10, IFNG, FAS. Enrichment of key cell types, including T, B, NK cells, is observed in canine DLE. Canine, mouse and human DLE share similar proinflammatory profiles. Canine DLE exhibits downregulated skin homeostatic and immune regulatory genes.
Collapse
|